Small Business Innovation Research (SBIR)
The Small Business Innovation Research (SBIR) program is a set-aside program (3.2% of an agency’s extramural budget in FY2022) for domestic small business concerns to engage in Research/Research and Development (R/R&D) that has the potential for commercialization and public benefit. The SBIR program was established under the Small Business Innovation Development Act of 1982 (P.L. 97-219).
CDC’s SBIR Program targets innovations in diagnostics, data science (e.g., artificial intelligence (AI), machine learning, etc.), surveillance, occupational safety and health, and public health to support the health promotion and disease prevention needs of CDC. Today, CDC’s SBIR program is under the stewardship of the Office of Science (OS), Office of Technology and Innovation (OTI). CDC is committed to ensuring a competitive award process that results in projects of scientific excellence and technological innovation with the potential for commercialization.
The Small Business Innovation Research (SBIR) Program encourages small business to engage in research and development (R&D). Program goals include:
- Use small businesses to stimulate technological innovation,
- Strengthen the role of small business in meeting Federal R/R&D needs,
- Increase private-sector commercialization of innovations derived from Federal research and development funding,
- Increase small business participation in Federal R/R&D, and
- Foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program.
Only U.S.—based small business concerns (SBCs) are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in the current SBIR parent funding opportunity announcements available at the NIH Small Business Funding Opportunities.
Three Phases of SBIR
Funding is awarded competitively and is available for only Phases I and II of the SBIR Program:
- Phase I awards contracts up to $243,500 for approximately 6 months and Phase I grants awards up to $275,766* for approximately 6 months to support exploration of the technical merit or feasibility of an idea or technology.
- Phase II awards projects that expand Phase I results. Awards can range up to $1,838,436* for a project period of up to 2 years. During this time, the R&D work is performed, and the developer evaluates commercialization potential.
- Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. At this stage, the small business must find funding in the private sector or other non-SBIR federal agency funding.
*CDC has a waiver from the Small Business Administration to exceed these budgets for CDC’s Grant Topic Areas of Interest.
CDC SBIR Funding Opportunities
- CDC participates in the SBIR Parent Grant Solicitation for the National Institutes of Health (NIH), CDC, and Food and Drug Administration (FDA): Clinical Trial Not Allowed (PA-22-176) and Clinical Trial Required (PA-22-177). See HHS Program Descriptions document pages 161-193 for CDC’s research topics of interest.
- CDC participates along with the NIH in the PHS 2023-1 SBIR Contracts Solicitation. The Contract receipt date was November 4, 2022, 5 p.m. EDT.
- For more information about individual funded projects, visit the NIH RePorter.
SBIR Report Fraud, Waste, and Abuse
The Office of Inspector General (OIG) promotes the effective, efficient, and economical operation of Department of Health and Human Services (HHS) programs and operations through audits, inspections, investigations, and other reviews. The HHS OIG Hotline accepts tips from all sources about potential fraud, waste, abuse, and mismanagement in HHS programs. The reporting individual should indicate the fraud, waste, and/or abuse concerns for a SBIR grant or contract, if relevant.
What types of fraud are found in the SBIR Programs?
Knowing the Rules
Which SBIR rules should you become particularly familiar with?
What happens if you break the rules?
Please use the following if you want additional information or want to report wrongdoing:
Please direct all inquiries to: Office of Technology and Innovation, SBIR@cdc.gov, or 404-718-1386.
For questions related to fraud, waste, or abuse, contact us or the Strategic Business Initiatives (SBI) Unit, Office of the Chief Operating Officer (OCOO), at ERM@cdc.gov.